Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: PaxMedica Inc. PXMD

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD

PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement

In a significant corporate update, PaxMedica (NASDAQ: PXMD) today filed an 8-K with the Securities and Exchange Commission, disclosing its successful compliance with Nasdaq’s minimum equity requirements. Journey Towards Compliance PaxMedica’s compliance journey began on December 6, 2022, when Nasdaq … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in the United States. While ASD is not uncommon, … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced the completion of a type-B meeting … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently reported the closing of its public offering. … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for … Continue reading

Posted in PaxMedica Inc. PXMD | Leave a comment